logo-loader
viewBiocept Inc

Full interview: Biocept making great strides with its Switch-Blocker technology

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive that a peer-review journal named PLOS ONE has published validation results showing a higher sensitivity of the San Diego-based liquid biopsy provider's Target Selector, including its Switch-Blocker technology, which tests for rare cancers in plasma circulating tumor DNA.

Nall says, along these lines, Biocept was recently awarded a patent on its Switch-Blocker technology in South Korea, bringing Biocept's patent total to 37.

Quick facts: Biocept Inc

Price: 0.309 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $13.05 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Biocept 'one of the first' liquid biopsy providers to detect...

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive the California-based company's Target Selector liquid biopsy tests are now available to detect cancer biomarkers in cerebrospinal fluid. Nall says the company has also managed to win a US patent for its liquid biopsy cancer testing...

6 days, 16 hours ago

2 min read